Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Clinical Evaluation of Combination Immunotherapy for Renal Cell Carcinoma

NCT07510334 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07510334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07510334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Clinical Evaluation of Combination Immunotherapy for Renal Cell Carcinoma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
April 21, 2026
Completion date
August 1, 2033
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, metastatic clear cell renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8